StreetInsider.com News Articles

ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process

Thu, 15 Oct 2026 07:00:00 -0400

Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield

No Thromboembolic Events Were Reported for ADMA IVIG Products Manufactured Using the Optimized Process During the Postmarketing Surveillance Period Evaluated

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced the publication of a peer-reviewed article in Frontiers in Cardiovascular Medicine detailing new data from the Company’s optimized, proprietary intravenous immune

ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process

Thu, 15 Oct 2026 07:00:00 -0400

Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield

No Thromboembolic Events Were Reported for ADMA IVIG Products Manufactured Using the Optimized Process During the Postmarketing Surveillance Period Evaluated

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Fri, 07 Aug 2026 14:21:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 7, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of ADMA Biologics, Inc. who were adversely affected if they purchased the Company's securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"). This action is pending in the United States District

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Fri, 07 Aug 2026 14:21:00 -0400

Form SCHEDULE 13G ADMA BIOLOGICS, INC. Filed by: STATE STREET CORP

Fri, 07 Aug 2026 08:23:00 -0400

si-local-file:///var/storage/secattach/20260807/26887954.html

Form SCHEDULE 13G ADMA BIOLOGICS, INC. Filed by: STATE STREET CORP

Fri, 07 Aug 2026 08:23:00 -0400

si-local-file:///var/storage/secattach/20260807/26887954.html

Form 10-Q ADMA BIOLOGICS, INC. For: Jun 30

Wed, 05 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260805/26875943.html

Form 10-Q ADMA BIOLOGICS, INC. For: Jun 30

Wed, 05 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260805/26875943.html

Form 8-K ADMA BIOLOGICS, INC. For: Aug 05

Wed, 05 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260805/26874381.html

Form 8-K ADMA BIOLOGICS, INC. For: Aug 05

Wed, 05 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260805/26874381.html

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 05 Aug 2026 16:05:00 -0400

2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year

2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year

BIVIGAM Utilization Stabilized with Sequential Improvement in Demand and Revenue

2Q 2026 GAAP Net Income of $37.8 Million, Increasing 11% Year-over-Year

2Q 2026 Adjusted Net Income(1) of $39.0 Million, Increasing 8% Year-over-Year

2Q 2026 GAAP Basic EPS of $0.17, Increasing 17% Year-over-Year

2Q 2026 Adjusted EBITDA(2) of $61.8 Million, Increasing 22% Year-over-Year

Strong Balance Sheet and Financial Flexibility Support Continued Execution

ACAAI Abstract

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 05 Aug 2026 16:05:00 -0400

2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year

2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year

BIVIGAM Utilization Stabilized with Sequential Improvement in Demand and Revenue

2Q 2026 GAAP Net Income of $37.8 Million, Increasing 11% Year-over-Year

2Q 2026 Adjusted Net Income(1) of $39.0 Million, Increasing 8% Year-over-Year

2Q 2026 GAAP Basic EPS of $0.17, Increasing 17% Year-over-Year

2Q 2026 Adjusted EBITDA(2) of $61.8 Million, Increasing 22% Year-over-Year

Strong Balance Sheet and Financial Flexibility Support Continued Execution

ACAAI Abstract

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 05 Aug 2026 16:05:00 -0400

2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year

2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year

BIVIGAM Utilization Stabilized with Sequential Improvement in Demand and Revenue

2Q 2026 GAAP Net Income of $37.8 Million, Increasing 11% Year-over-Year

2Q 2026 Adjusted Net Income(1) of $39.0 Million, Increasing 8% Year-over-Year

2Q 2026 GAAP Basic EPS of $0.17, Increasing 17% Year-over-Year

2Q 2026 Adjusted EBITDA(2) of $61.8 Million, Increasing 22% Year-over-Year

Strong Balance Sheet and Financial Flexibility Support Continued Execution

ACAAI Abstract

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 05 Aug 2026 16:05:00 -0400

2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year

2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year

BIVIGAM Utilization Stabilized with Sequential Improvement in Demand and Revenue

2Q 2026 GAAP Net Income of $37.8 Million, Increasing 11% Year-over-Year

2Q 2026 Adjusted Net Income(1) of $39.0 Million, Increasing 8% Year-over-Year

2Q 2026 GAAP Basic EPS of $0.17, Increasing 17% Year-over-Year

2Q 2026 Adjusted EBITDA(2) of $61.8 Million, Increasing 22% Year-over-Year

Strong Balance Sheet and Financial Flexibility Support Continued Execution

ACAAI Abstract

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 05 Aug 2026 16:05:00 -0400

2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year

2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year

BIVIGAM Utilization Stabilized with Sequential Improvement in Demand and Revenue

2Q 2026 GAAP Net Income of $37.8 Million, Increasing 11% Year-over-Year

2Q 2026 Adjusted Net Income(1) of $39.0 Million, Increasing 8% Year-over-Year

2Q 2026 GAAP Basic EPS of $0.17, Increasing 17% Year-over-Year

2Q 2026 Adjusted EBITDA(2) of $61.8 Million, Increasing 22% Year-over-Year

Strong Balance Sheet and Financial Flexibility Support Continued Execution

ACAAI Abstract

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 05 Aug 2026 16:05:00 -0400

2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year

2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year

BIVIGAM Utilization Stabilized with Sequential Improvement in Demand and Revenue

2Q 2026 GAAP Net Income of $37.8 Million, Increasing 11% Year-over-Year

2Q 2026 Adjusted Net Income(1) of $39.0 Million, Increasing 8% Year-over-Year

2Q 2026 GAAP Basic EPS of $0.17, Increasing 17% Year-over-Year

2Q 2026 Adjusted EBITDA(2) of $61.8 Million, Increasing 22% Year-over-Year

Strong Balance Sheet and Financial Flexibility Support Continued Execution

ACAAI Abstract

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 05 Aug 2026 16:05:00 -0400

2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year

2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year

BIVIGAM Utilization Stabilized with Sequential Improvement in Demand and Revenue

2Q 2026 GAAP Net Income of $37.8 Million, Increasing 11% Year-over-Year

2Q 2026 Adjusted Net Income(1) of $39.0 Million, Increasing 8% Year-over-Year

2Q 2026 GAAP Basic EPS of $0.17, Increasing 17% Year-over-Year

2Q 2026 Adjusted EBITDA(2) of $61.8 Million, Increasing 22% Year-over-Year

Strong Balance Sheet and Financial Flexibility Support Continued Execution

ACAAI Abstract

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 05 Aug 2026 16:05:00 -0400

2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year

2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year

BIVIGAM Utilization Stabilized with Sequential Improvement in Demand and Revenue

2Q 2026 GAAP Net Income of $37.8 Million, Increasing 11% Year-over-Year

2Q 2026 Adjusted Net Income(1) of $39.0 Million, Increasing 8% Year-over-Year

2Q 2026 GAAP Basic EPS of $0.17, Increasing 17% Year-over-Year

2Q 2026 Adjusted EBITDA(2) of $61.8 Million, Increasing 22% Year-over-Year

Strong Balance Sheet and Financial Flexibility Support Continued Execution

ACAAI Abstract

ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches

Wed, 05 Aug 2026 12:59:00 -0400

Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or the "Company") (NASDAQ: ADMA) may have breached their fiduciary duties or otherwise failed to oversee and manage the Company appropriately. The investigation also concerns whether ADMA Biologics and its shareholders may have been harmed as a result.
If you currently own ADMA Biologics common stock, you may have rights in connection with this investigation.
What Is the Investigation About?
The investigation concerns allegations regarding ADMA Biologics' reported growth, distribution practices, related-party disclosures, and corporate oversight.
In

ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches

Wed, 05 Aug 2026 12:59:00 -0400

Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or the "Company") (NASDAQ: ADMA) may have breached their fiduciary duties or otherwise failed to oversee and manage the Company appropriately. The investigation also concerns whether ADMA Biologics and its shareholders may have been harmed as a result.
If you currently own ADMA Biologics common stock, you may have rights in connection with this investigation.
What Is the Investigation About?
The investigation concerns allegations regarding ADMA Biologics' reported growth, distribution practices, related-party disclosures, and corporate oversight.
In

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Mon, 03 Aug 2026 15:01:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 3, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of ADMA Biologics, Inc. who were adversely affected if they purchased the Company's securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"). This action is pending in the United States District

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Mon, 03 Aug 2026 15:01:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 3, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of ADMA Biologics, Inc. who were adversely affected if they purchased the Company's securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"). This action is pending in the United States District

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Fri, 31 Jul 2026 13:38:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 31, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of ADMA Biologics, Inc. who were adversely affected if they purchased the Company's securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"). This action is pending in the United States District

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Fri, 31 Jul 2026 13:38:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 31, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of ADMA Biologics, Inc. who were adversely affected if they purchased the Company's securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"). This action is pending in the United States District

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Wed, 29 Jul 2026 16:41:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 29, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of ADMA Biologics, Inc. who were adversely affected if they purchased the Company's securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"). This action is pending in the United States District